Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study

作者：Ziming Li, Yan Wang, Yuping Sun, Linlin Wang, Xingya Li, Longhua Sun, Zhiyi He, Haiyan Yang, Yongsheng Wang, Qiming Wang, Zhengbo Song, Wei Hong, Yong Wang, Guohao Xia, Yan Yu, Min Peng, Yong Song, Donglin Wang, Rui Meng, Jian Fang, Yongzhong Luo, Wenhua Liang, Sheng Hu, Zhihui Wang, Ke Song, You Li, Lulu Yang, Wei Shi, Shun Lü · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00012-9 · 被引用次数：50 · 研究领域：HER2/EGFR in Cancer Research、Lung Cancer Treatments and Mutations、Peptidase Inhibition and Analysis